151 related articles for article (PubMed ID: 12413244)
1. Sample size calculation for a proof of concept study.
Yin Y
J Biopharm Stat; 2002 May; 12(2):267-76. PubMed ID: 12413244
[TBL] [Abstract][Full Text] [Related]
2. Design and analysis of a clinical trial using previous trials as historical control.
Schoenfeld DA; Finkelstein DM; Macklin E; Zach N; Ennist DL; Taylor AA; Atassi N;
Clin Trials; 2019 Oct; 16(5):531-538. PubMed ID: 31256630
[TBL] [Abstract][Full Text] [Related]
3. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
4. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
6. Bayesian Phase II optimization for time-to-event data based on historical information.
Bertsche A; Fleischer F; Beyersmann J; Nehmiz G
Stat Methods Med Res; 2019 Apr; 28(4):1272-1289. PubMed ID: 29284369
[TBL] [Abstract][Full Text] [Related]
7. Rilutek (Riluzole) may extend survival in amyotrophic lateral sclerosis.
J Neurosci Nurs; 1996 Aug; 28(4):275. PubMed ID: 8880606
[No Abstract] [Full Text] [Related]
8. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function.
Pearce M; Hee SW; Madan J; Posch M; Day S; Miller F; Zohar S; Stallard N
BMC Med Res Methodol; 2018 Feb; 18(1):20. PubMed ID: 29422021
[TBL] [Abstract][Full Text] [Related]
9. The value of information and optimal clinical trial design.
Willan AR; Pinto EM
Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
[TBL] [Abstract][Full Text] [Related]
10. Sample size calculation for a historically controlled clinical trial with adjustment for covariates.
O'Malley AJ; Normand SL; Kuntz RE
J Biopharm Stat; 2002 May; 12(2):227-47. PubMed ID: 12413242
[TBL] [Abstract][Full Text] [Related]
11. Sample size determination for cost-effectiveness trials.
Willan AR
Pharmacoeconomics; 2011 Nov; 29(11):933-49. PubMed ID: 21988292
[TBL] [Abstract][Full Text] [Related]
12. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
[TBL] [Abstract][Full Text] [Related]
13. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
14. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.
Tavakoli M; Malek M
J Neurol Sci; 2001 Oct; 191(1-2):95-102. PubMed ID: 11676998
[TBL] [Abstract][Full Text] [Related]
15. Bayesian sample-size determination methods considering both worthwhileness and unpromisingness for exploratory two-arm randomized clinical trials with binary endpoints.
Kakizume T; Zhang F; Kawasaki Y; Daimon T
Pharm Stat; 2020 Jan; 19(1):71-83. PubMed ID: 31496045
[TBL] [Abstract][Full Text] [Related]
16. The sample size for a clinical trial: a Bayesian-decision theoretic approach.
Halpern J; Brown BW; Hornberger J
Stat Med; 2001 Mar; 20(6):841-58. PubMed ID: 11252007
[TBL] [Abstract][Full Text] [Related]
17. Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold.
Armon C; Guiloff RJ; Bedlack R
Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Sep; 3(3):109-12. PubMed ID: 12495570
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.
Messori A; Trippoli S; Becagli P; Zaccara G
Pharmacoeconomics; 1999 Aug; 16(2):153-63. PubMed ID: 10539396
[TBL] [Abstract][Full Text] [Related]
19. Bayesian sample size determination under hypothesis tests.
Zhang X; Cutter G; Belin T
Contemp Clin Trials; 2011 May; 32(3):393-8. PubMed ID: 21199689
[TBL] [Abstract][Full Text] [Related]
20. Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis.
Healy BC; Schoenfeld D
Muscle Nerve; 2012 Oct; 46(4):506-11. PubMed ID: 22987690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
